Credit: FDA. The approval was based on data from a phase 1 study that compared the pharmacokinetics, safety, tolerability, and immunogenicity of Hadlima 100mg/mL to 50mg/mL. The Food and Drug ...
HADLIMA is currently indicated for psoriatic arthritis, plaque psoriasis, and hidradenitis suppurativa, among others. Samsung Bioepis Co., Ltd. and Organon & Co. announced that the FDA has accepted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results